Technical Analysis for PRRUF - Immutep Limited

Grade Last Price % Change Price Change
grade F 0.01 0.00% 0.0000
PRRUF closed unchanged on Friday, August 30, 2019, on 11 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A Down
See historical PRRUF trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Hot IPO Pullback Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Gapped Down Weakness 0.00%
Narrow Range Bar Range Contraction -50.00%
Gapped Up Strength -50.00%
Hot IPO Pullback Bullish Swing Setup 0.00%

Older signals for PRRUF ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its therapeutics are based on the lymphocyte activation gene-3 (LAG-3) Ig fusion protein, a cell surface molecule that plays a role in regulating T cells. The company's lead product candidate is eftilagimod alpha (efti) with KEYTRUDA therapy, an antigen presenting cell activator, which is in a Phase IIb clinical trial as a chemoimmunotherapy for metastatic breast cancer, as well as in a Phase I combination therapy trial in metastatic melanoma. Its other products include IMP731, a LAG-3 depleting antibody, which is in a Phase I clinical trial for use in autoimmune diseases; IMP701, a LAG-3 antagonist antibody that is in a Phase I/II clinical trial, which is used for the treatment of cancer; and IMP761, an agonist of LAG-3 for treating autoimmune diseases. The company has operations in Europe, Australia, and the United States. Immutep Limited has a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc., to evaluate the combination of efti with avelumab, a human anti-PD-L1 antibody, in patients with advanced solid malignancies; and partnerships with GlaxoSmithKline, Novartis, and EOC Pharma for the development of LAG-3 product candidates. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited is headquartered in Sydney, Australia.
Biotechnology Cancer Clinical Medicine Drugs Treatment Of Cancer Autoimmune Diseases Alpha Monoclonal Antibodies Cancer Treatments Antineoplastic Drugs Biological Products Merck Metastatic Breast Cancer Metastatic Melanoma Breakthrough Therapy Immunotherapeutic Products Immutep
Is PRRUF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 1 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 0.055
52 Week Low 0.01
Average Volume 39,180
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 0.0
10-Day Moving Average 0.0195
Average True Range 0.0107
ADX 0.0
+DI 46.2777
-DI 40.5097
Chandelier Exit (Long, 3 ATRs ) 0.0229
Chandelier Exit (Short, 3 ATRs ) 0.0421
Upper Bollinger Band 0.0
Lower Bollinger Band 0.0
Percent B (%b) 0.0
BandWidth 0.0
MACD Line -0.0033
MACD Signal Line -0.0017
MACD Histogram -0.0016
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0100
Resistance 3 (R3) 0.0100 0.0100 0.0100
Resistance 2 (R2) 0.0100 0.0100 0.0100 0.0100
Resistance 1 (R1) 0.0100 0.0100 0.0100 0.0100 0.0100
Pivot Point 0.0100 0.0100 0.0100 0.0100 0.0100
Support 1 (S1) 0.0100 0.0100 0.0100 0.0100 0.0100
Support 2 (S2) 0.0100 0.0100 0.0100 0.0100
Support 3 (S3) 0.0100 0.0100 0.0100
Support 4 (S4) 0.0100